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ABSTRACT
Two experiments assessed the potential of altrenogest, an artificial progestogen, and
deslorelin acetate, a gonadotropin-releasing hormone (GnRH) agonist, for suppressing estrus and
ovulation in cyclic mares. In the first experiment, mares were administered a luteolytic dose of
prostaglandin-F2α on d 6 of diestrus, and were then treated with 1 of 3 formulations of altrenogest
in slow-release vehicle (6 mares/group): 1) Biorelease altrenogest LA150 (225 mg total as a 1.5
mL injection); 2) Biorelease altrenogest LA225 (225 mg total as a 1.0 mL injection); or 3)
Biorelease altrenogest LA225 (450 mg total as a 2.0 mL injection). Six control mares received
vehicle. Compared to control mares (10.0 days), time to ovulation was greater (P < 0.01) for all
mares receiving altrenogest (17.5 days overall); there was no difference (P > 0.5) among groups
receiving altrenogest. Control mares (6 out of 6) first displayed estrus an average of 4.5 days
after prostaglandin-F2 injection; of the 18 mares receiving altrenogest, 11 displayed first estrus
at an average of 13.5 days (P < 0.02 relative to controls) and there was no difference (P > 0.19)
among groups. It was concluded that the 3 formulations of altrenogest were equally effective in
delaying estrus and ovulation in cyclic mares. It is suggested that a 10-day injection interval
could be used to keep mares out of heat for extended periods of time. The second experiment
was similar to the first, except that there were 2 groups: 1) control mares that received a vehicle
injection and 2) mares that received an i.m. injection of 1.5 g of deslorelin acetate in
biodegradable microparticles. Administration of deslorelin did not affect (P > 0.1) the day of first
onset of estrus or the day of ovulation. There was a tendency (P = 0.08) for deslorelin treated
mares (3 out of 7 vs. 0 out of 6 controls) to not show estrus at the expected time, even though
they experienced luteolysis and ovulation. It was concluded that injection of 1.5 g of deslorelin
acetate was not an effective method for suppressing estrus and ovulation in cyclic mares.
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INTRODUCTION
Considerable research has been performed over the years in an effort to induce seasonally
anovulatory mares to display estrus and ovulate in winter. In contrast, less effort has been
expended in devising a reliable method for inhibiting the normal displays of estrus and
occurrence of ovulation in mares. Two practical situations in the horse industry exist when
owners desire this inhibition: 1) in performance mares, behavioral estrus can interfere with a
mare's training and response, and is thus unwanted, and 2) in recipient mares in embryo transfer
programs, it is more efficient to have mares in a neutral state (noncyclic) so that they can be
manipulated more easily by hormone therapy. The first situation (keeping mares out of estrus)
might be achieved by endocrine manipulation, such as the long-term use of a progestogen, or
perhaps by a total shut down of the reproductive system, analogous to the seasonal anovulatory
state. The second situation, however, would likely require a total shut down, such that the mare
would present a “blank slate” to be manipulated hormonally.
The research presented herein was designed to test the possibility of using one of two
commonly available hormonal analogs, altrenogest and deslorelin acetate, as a means of
inhibiting behavioral estrus displays and suppressing ovulation in normally cyclic mares.
Altrenogest is an orally active progestogen originally developed for synchronizing estrus in
mares, and deslorelin acetate is a GnRH agonist that is commonly used to hasten ovulation in
cyclic mares.
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CHAPTER I
REVIEW OF LITERATURE
Equine Hypothalamic-Pituitary-Gonadal Axis
Previous research described the relationship between the hypothalamic-pituitary-gonadal
axis and reproductive function (Ginther, 1992). The reproductive axis is controlled by the brain
via chemical neurotransmitters that impinge on the hypothalamus, which contains neurons that
produce and secrete gonadotropin releasing hormone (GnRH; Guyton and Hall, 1996). In the
mare, this neuropeptide is released in a pulsatile manner in response to the change in season and
position in the estrous cycle. Upon stimulation, GnRH is released from nerve endings at the
median eminence of the hypothalamus, where it is stored in secretory granules; it then travels
through portal vessels to reach the adenohypophysis where it binds to receptors on gonadotropes
in the pars distalis of the hypothalamus (Ginther, 1992; Guyton and Hall, 1996). Gonadotropin
releasing hormone stimulates gonadotropes to synthesize and secrete lutenizing hormone (LH)
and follicle stimulating hormone (FSH; Irvine and Alexander, 1993; Guyton and Hall, 1996).
Concentration of these hormones depends on the pulsatile fashion in which GnRH is released
(Alexander and Irvine, 1993). If the pulse frequency is between 2 and 4 pulses per day, FSH is
the predominant homone, causing follicular recruitment. If the pulse frequency high (intervals of
every 2 h or less), LH predominates and ovulation is induced (Alexander and Irvine, 1993). The
ovary is dependent on the secretion of FSH and LH for development and ovulation. Receptors
for FSH are found on the granulosa cells in the ovary, whereas LH receptors are found on the
thecal cells (Guyton and Hall, 1996). Maturing follicles produce estradiol, which is released into
the peripheral circulation and causes the surge of LH that will result in ovulation (Morel, 2008).

2

Therefore, without control of the gonads by the hypothalamic-hypophyseal axis, the mare would
have minimal follicular growth and no cyclic estrous activity.
Estrus Cycle of the Mare
The estrous cycle is the repetitive sequence of events that prepare the mare for
conception (Daels and Hughes, 1993). The estrus cycle of the mare begins at puberty and last an
average of 21.7 days per cycle, being slightly longer early and late in the breeding season, and
consistently around 21 days at the peak of the breeding season (April through September;
Ginther, 1992). The cycle is a pattern of events, both physiological and behavioral, which are
under hormonal control (Daels and Hughes, 1993). Control of the estrous cycle is governed by
the hypothalamic-pituitary axis. The cycle is divided into two phases, estrus and diestrus. The
estrous phase lasts on average 6.5 days and is the period in which a dominant follicle emerges on
one ovary and the mare becomes sexually receptive (Ginther 1992). Ovulation occurs an average
of 24 h prior to the end of sexual receptivity (i.e., on the penultimate day of the estrous period).
The diestrus phase typically lasts 15 to 16 days and is the period of elevated plasma progesterone
concentrations and nonreceptivity to the stallion. Diestrus ends when the corpus luteum (CL)
regresses and estrus begins again 1 to 2 days later (Daels and Hughes 1993).
The hypothalamic-pituitary axis is controlled by day length, which is perceived by the
pineal gland (Sharp and Cleaver, 1993). The pineal gland secretes melatonin, which is thought to
affect dopaminergic neurons in the hypothalamus that control prolactin secretion by the pituitary
gland in other species (Lincoln and Tortonese, 1995). Either directly on GnRH secreting
neurons, or indirectly through other pathways, elevated melatonin concentrations during the long
nights of winter also result in reduced gonadotropin production and secretion by the pituitary
gland (Sharp and Davis, 1993) via reduced production and secretion of GnRH (Silvia et al.,
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1987). As day length increases in late winter (in the northern hemisphere), the melatonin
influence diminishes and GnRH is produced and secreted in greater amounts, resulting in a
stimulation of pituitary LH and FSH and a continuation of estrous cycling.
Plasma LH concentrations are low from days 5 to 16 of diestrus and begin to rise with
luteolysis. After luteolysis, the negative feedback by progesterone on pituitary LH secretion is
removed and the increasing estrogen secretion from the follicles, particularly the emerging
dominant follicle, greatly stimulates LH secretion throughout the estrous period. This LH
stimulates development and maturation of the primary follicle in a positive feedback loop (Daels
and Hughes, 1993); the high LH concentrations eventually lead to ovulation and subsequent CL
formation.
Plasma FSH concentrations are suppressed by two ovarian factors from the dominant
follicle: estrogen (primarily estradiol) and inhibin, a protein hormone (Ginther, 1992). The high
plasma FSH during diestrus stimulates the growth and maturation of follicles, as well as estrogen
secretion. Secretion of FSH during diestrus is sometimes biphasic, with peaks occurring soon
after ovulation and again towards the end of diestrus (Alexander and Irvine, 1993). Such
biphasic secretion is not observed consistently in all mares (Ginther, 1992). Once a follicle
reaches the preovulatory stage, the high secretion rates of estradiol and inhibin greatly suppress
FSH secretion, which is low albeit measurable throughout the estrous period.
The behavorial changes associated with estrus are thought to be primarily due to
estrogens secreted by the developing follicles. Granulosa cells within the follicle convert
androgens produced by the thecal cells (an LH dependent action) into estradiol 17-beta via the
aromatase enzyme system, and this action is FSH dependent (Daels and Hughes 1993). Plasma
estradiol concentrations peak just prior to ovulation, and return to very low levels shortly after
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ovulation. The decline in estradiol concentrations prior to ovulation are due to the release of the
granulosa cells into the follicular fluid, which is part of the ovulation process (Morel, 2008).
Formation of the CL occurs shortly post ovulation, and progesterone concentrations are
measurably elevated in jugular plasma within approximately 24 h (Ginther, 1992). The luteal
tissue contained within the CL is in part derived from the follicular thecal cells (Morel, 2008),
although granulosa cells are thought to also contribute to the luteal cells population (Squires,
1993). Plasma progesterone concentrations rise for 5 to 6 days post ovulation and reach their
maximum near 10 ng/mL. These concentrations are maintained until day 15 to 16 of the cycle,
and drop 4 to 5 days prior to the next ovulation (Daels and Hughes, 1993). The rise in
progesterone concentrations, which are typically inhibitory to LH secretion (Thompson et al.,
1991), causes a gradual reduction in LH concentrations in early diestrus. The elevated
progesterone concentrations in diestrus are, if anything, slightly stimulatory on FSH secretions
(McNeil-Wiest et al., 1988; Thompson et al., 1991).
The relatively rapid formation of the CL with its associated progesterone secretion is
responsible for the shift from estrous displays to those of diestrus (i.e., nonreceptivity to stallion;
Ginther, 1992). Progesterone blocks displays of estrus in mares, even in the presence of
estradiol. Similarly, even though estrogen is stimulatory to LH concentrations in mares in the
absence of progesterone, the combination of estrogen and progesterone acts synergistically to
inhibit LH secretion more so than a similar dose of progesterone alone (Garcia and Ginther,
1978).
Progestogens and Equine Reproduction
Suppression of the estrous cycle is often desired by owners of performance horses to
decrease signs of estrus that are often detrimental to the ability of their horse to compete at the
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highest level. Previous research revealed that oil based injections of progesterone were able to
block estrus and ovulation (Loy and Swan, 1966). There have been many attempts at using
synthetic progestogens to circumvent the estrous cycle with minor successes. The failure of most
synthetic progestogen preparations is the inefficiency in binding to the progesterone receptor.
Previous studies tested the effects of medoxyprogestone acetate on quarter horses mares and
found that it had no significant effects on the estrus cycle of the mare (McCue, 2003). These
results were later validated by Storer et al. in 2009.
Currently, the only FDA approved method to suppress estrous is altrenogest, which is an
orally active progestogen marketed as Regumate (Intervet, Inc., Millsboro, DE). Altrenogest is
sold as a solution in oil and is fed at 0.044 mg/kg of body weight per day (McCue, 2003).
Altrenogest is the 17α-allyl derivative of trenbolone, an anabolic agent similar to testosterone.
Regumate is approved by the Federal Drug Administration for the following uses: 1) to facilitate
attainment of regular cycles during the transition period from winter anestrus to the
physiological breeding season, 2) to facilitate management of the mare exhibiting prolonged
estrus during the transition period, and 3) to permit scheduled breeding of mares during the
physiological breeding season (http://www.regu-mate.com/label.asp). Behavorial suppression of
estrus occurs within 2 to 3 days of administration (Hodgson et al., 2005), and will continue as
long as the drug is administered at the recommended dose. One drawback of Regumate as sold is
that it requires daily application. A means of delivering altrenogest, which is now off patent,
without daily feeding is highly desirable.
Use of GnRH and GnRH Agonists in Equine Reproduction
With the revelation of the amino acid structure of GnRH in the 1970's (Nair and Schally,
1972), peptide chemists soon began testing various modifications to the original structure in an
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effort to produce longer acting, more active analogs (Coy et al., 1973). Naturally occurring
GnRH is a decapeptide synthesized and stored in terminal granules in the median eminence.
Substitutions of the sixth amino acid, glycine, and deletion of the carboxyl terminal amino acid,
also glycine, with the addition of an ethyl amide group resulted in analogs with much greater
half-lives in peripheral circulation and much greater biologic activity (Coy et al., 1974). Several
of these analogs were extensively tested for their efficacy to induce ovulation in estrous mares
(Irvine, 1993), and a biodegradable capsule formulation of deslorelin acetate was eventually
marketed as Ovuplant in the late 1990's.
A major problem with the use of GnRH analogs in other species has been the
development of refractoriness, or down regulation of pituitary responsiveness to GnRH
(D’Occhio et al., 2000). Fitzgerald et al. (1993) first reported the inhibitory effect of goserelin
acetate on ovulation in seasonally cyclic mares, but with variable results. Although mares seem
to be less amenable to down regulation (Porter et al., 1997), the widespread use of Ovuplant after
its appearance on the market revealed that it had undesirable side-effects in mares not conceiving
to an Ovuplant-induced ovulation (Johnson et al., 2000). Those mares displayed a delayed return
to estrus and delayed follicular growth (Johnson et al., 2000; Farquhar et al., 2001; Blanchard et
al. 2002). Johnson et al. (2002) subsequently reported that mares treated with Ovuplant had
greatly reduced plasma LH and FSH concentrations and a reduced sensitivity to GnRH
challenges for up to 10 days after ovulation. About the same time, McCue et al. (2002) and
Wendt et al., (2002) showed that if the implant was removed within 48 h after insertion, the
beneficial effect on ovulation was retained, but the lengthening of the interovulatory interval was
avoided. Similar to anecdotal evidence among horse breeders at the time, Johnson et al. (2000)
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also found that a small percentage of mares became totally anovulatory for the entire season after
Ovuplant administration, a fact that eventually led to Ovuplant being pulled from the U.S.
market.
It is due to this down-regulation by deslorelin acetate that it is now being considered as a
means of inhibiting, rather than stimulating, reproductive processes in mares. Deslorelin acetate
is readily available in large quantities now due to its poor performance as a commercial product
in Ovuplant. Ovuplant capsules contained 2.1 mg of deslorelin acetate. The question is whether
much larger doses of deslorelin, particularly in slow-release formulations, could cause complete
down regulation of the reproductive processes of mares.
Slow-release Drug Delivery Systems
Various approaches for slowing down the release of drugs, when injected into the body
or taken orally, have been developed over many years of research. Many texts and reviews are
available on the subject, and one recent online article covers the history and present state of the
science very well (Rhee et al., 2010). Basically, slow-release formulations can be divided into
several types: oil-based injectable solutions, injectable-drug suspensions, polymer-based
microspheres, and polymer-based in-situ formings (form hydophobic depots in aqueous
environment after injection). The oil-based injectable solutions and injectable drug suspensions
are capable of releasing drug for weeks after a single injection, while polymer-based
microspheres and in-situ gels may last for months (Rhee et al., 2010).
Sucrose acetate isobutyrate (SAIB) is an organic polymer that is soluble in ethanol and
falls into the latter category (polymer-based in situ formings) of slow-release formulations. It can
be easily mixed with drugs dissolved in ethanol, and when some or all of the ethanol is
evaporated under reduced pressure, it forms a solution that becomes very hydrophobic when
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injected into the body (Tipton, 2002). In 2000, Southern BioSystems, Inc. and Thorn
BioScience, LLC, announced the issuance of U.S. Patent 6,051,558, "Compositions Suitable for
Controlled Release of the Hormone GnRH and its Analogs," based on the SAIB system. That
patent was partially based on research from the LSU Agricultural Center in which three
deslorelin formulations were assessed for efficacy of induction of ovulation and for resulting
deslorelin concentrations produced in jugular blood over time. A copy of this patent can be
viewed online at www.everypatent.com/comp/pat6051558.html. Application of this same
technology for altrenogest injections more recently has led to the development of LA 150, an
injectable altrenogest formulation that delivers 225 mg of altrenogest in a 1.5-mL i.m. dose.
Storer et al. (2009) reported that application of this formulation to mares, when given
simultaneously with a luteolytic dose of Lutalyse (prostaglandin-F2α) during diestrus, resulted in
the occurrence of first estrus 12.7 days later, compared to 3.9 days for control mares. Moreover,
Storer et al. (2009) pointed out that the C.V. for days to ovulation (mean = 16.5 d) was 11%,
indicating a relatively tight grouping of the data around the mean, which meant that the LA 150
formulation should provide reliable timing of ovulation for prediction of breeding dates. The LA
150 formulation is, and has been, commercially available through BetPharm, a Lexington, KY,
based pharmacy and can be purchased online (www.betpharm.com).
Rationale for Present Experiments
Today's horse owners often have the desire to circumvent the horse's naturally occurring
physiological events (e.g., estrus) due to the need alter the horses temperament, behavior, or
reproductive cycle. Mares in heat are often unruly and behave poorly during show events.
Pharmaceutically affecting the natural heat cycles may provide the best solution to these
problems. The experiments described herein were designed to test two possible methods to
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suppress estrus and ovulation in normally cycling mares: 1) treatment with altrenogest in
long-acting (slow-release) vehicle formulations, and 2) treatment with a high dose of the potent
GnRH agonist, deslorelin acetate, also in a slow-releasing injection vehicle.
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CHAPTER II
EVALUATION OF SUSTAINED RELEASE ALTRENOGEST FORMULATIONS
FOR SUPPRESSING ESTRUS AND OVULATION IN MARES
Introduction
Progestogens are frequently used to prevent the expression of estrus in race, show, and
broodmares for periods of a week or longer. Unfortunately, daily treatments can be impractical
for the administration of altrenogest or progesterone to mares, being inconvenient and time
consuming. Recent advances in biodegradable, controlled-release drug delivery systems that
allow single administration products to replace prolonged daily progestin treatment protocols
have shown promise in mares (Storer et al., 2009). Such formulations can reduce labor and the
associated handling stress to the animals and offer veterinarians an important means of
maintaining effective compliance rates on farms with wide varieties of management systems.
The present experiment was designed to evaluate the effectiveness of a new formulation of
altrenogest (BET Pharm BioRelease LA225; www.betpharm.com) at two doses (225 versus 450
mg in 1 versus 2 mL) to the currently available altrenogest formulation (BET Pharm BioRelease
LA150, 225 mg in 1.5 mL; www.betpharm.com) for suppression of estrus following PGF2α
treatment of cyclic mares. It was hypothesized that the new formulation would be as effective as
the currently available formulation. For comparison, a dose of the new formulation twice that of
the first was included to determine whether it extended the period of suppression even further.
Materials and Methods
Twenty-four mares of light horse breeds, maintained on native grass pasture at the LSU
Agricultural Center horse farm in Baton Rouge, were used in May and June of 2010 for this
study. They were in good body condition (scores of at least 6; Henneke et al., 1993), and
ranged in age from 5 to 16 years. Verification of normal reproductive cyclicity was determined
11

by transrectal ultrasound scanning of the ovaries and daily detection for estrus with a vigorous
stallion.
For all mares, once ovulation was detected, Lutalyse (10 mg; Pfizer Animal Health;
https://animalhealth.pfizer.com/sites/pahweb/Pages/Global.aspx) was administered (i.m.) on the
7th day following ovulation (designated as day 0). Mares were simultaneously administered
(i.m.) a single injection of altrenogest in a delay-release vehicle (treated groups; n = 6 each) or
vehicle only (controls; n = 6). The treated groups received: 1) a single injection of Biorelease
altrenogest LA150, currently available commercially (www.betpharm.com; 225 mg total; 22.5
mg/day for 10 days as a 1.5-mL solution); 2) a single injection of a new formulation, altrenogest
LA225 (225 mg total; 22.5 mg/day for 10 days as a 1-mL solution); or 3) a single injection of the
new altrenogest LA225 at twice the dose (450 mg total; 45 mg/day for 10 days as a 2-mL
solution). As mares became available for treatment, group assignments were selected at random,
but with the limitation that each successive set of four mares would contain one mare in each
treatment group.
After injection, mares were checked for estrus daily and their ovaries were scanned for
assessment of follicular sizes every 3 days until a follicle of 30 mm or larger was detected.
Mares achieving 30-mm follicles were then scanned daily until ovulation. The disappearance of
a preovulatory follicle (>35 mm) and the presence of a bright echogenic structure at the location
of the previously observed follicle were taken to indicate ovulation. The day of ovulation was
considered the day that the preovulatory follicle was no longer present. In addition, jugular blood
samples were drawn daily, once a mare achieved a 30-mm follicle, until day 5 post-ovulation to
confirm a rise in progesterone concentrations.
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Estrous behavior was scored based on behavioral signs at each assessment. Mares
nonreceptive to the stallion (diestrus) received scores of -3, -2, or -1, based on the degree of
negativity they displayed; behavioral signs including kicking, biting, holding ears back,
switching of tail, or holding tail down tightly. Passive mares (mares failing to show either
positive or negative signs) were scored as 0. Mares displaying signs typical of estrus (lordosis
reflex, urinating, raising of the tail, or clitoral eversion) were scored as 1, 2, or 3, based on the
intensities of the signs.
Injection sites were monitored for 5 days after injections for signs of swelling and
sensitivity. Swelling was scored as 0 to 3 (0 = none, 1= slight -diameter of swelling up to 12.5
mm, 2 = moderate- diameter of swelling 12.5 to 25 mm, 3 = significant diameter of swelling
about 25 mm or larger). Sensitivity to touch (yes/no) and temperature elevation at site (yes/no)
were also recorded.
Days to ovulation and days to first estrus were analyzed by one-way ANOVA (SAS, SAS
Instit., Cary, NC). Injection site endpoints were analyzed by repeated measures ANOVA with
treatment as the main effect and time as the repeated effect. Differences between means were
assessed by the least significant difference test (Steel et al., 1997).
Results
The mean days to ovulation and mean days to first day of estrus are presented in Figure
2.1. All control mares ovulated after the injection of prostaglandin-F2α at an average of 10.0
days (range 8 to 13). All mares treated with altrenogest ovulated after prostaglandin-F2α
injection. Means for the 3 treated groups ranged from 16.8 to 17.8 d, and all were greater (P <
0.002) relative to controls; there was no difference (P > 0.59) among the groups receiving
altrenogest.
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Figure 2.1. Days from treatment to ovulation (left panel) and to first estrus (right panel) for
control mares and mares treated with a single injection of Biorelease altrenogest LA 150 (225
mg; 1.5 mL) versus Biorelease altrenogest LA 225 at 225 mg (1 mL) or 450 mg (2 mL). Vertical
bars indicate ranges for each group. For both ovulation and estrus data, means for all treatment
groups were greater (P < 0.02) than for controls; there was no difference among means for
treated groups. Numbers inside bars for estrus means indicate the number of mares (of 6) that
did not show estrus with their post-treatment ovulation; means are based on those mares that did
display estrus. Pooled SEM were 2.0 days and 2.2 days for days to ovulation and days to first
estrus, respectively.
All control mares displayed estrus after prostaglandin-F2α injection, starting an average of
4.5 days after injection. Not all mares treated with altrenogest displayed estrus after
prostaglandin-F2α injection in association with the detected ovulation (2 or 3 mares in each group
did not). Mean day of first estrus for the remaining mares in the treated groups ranged from 11.3
to 15.0 d, and were all greater (P < 0.02) relative to controls; there was no difference (P > 0.19)
among the treated groups.
The mean injection site swelling and sensitivity scores are presented in Figure 2.2.
Injection site temperature scores were all zero, and are not presented. Swelling scores were
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Figure 2.2. Swelling (left panel) and sensitivity (right panel) scores for the site of injection for
control mares and mares treated with a single injection of Biorelease altrenogest LA 150 (225
mg; 1.5 mL) versus Biorelease altrenogest LA 225 at 225 mg (1 ml) or 450 mg (2 mL). The
vertical line in the left panel represents the least-significant difference value for assessment of
differences between means within any given day (P < 0.05). Swelling scores are based on a 0 to
3 scale: 0 = none; 1 = slight; 2 = moderate; and 3 = significant. Sensitivity scores are based on 0
= no and 1 = yes. Site of injection scores for temperature elevation taken on the same days were
all 0 (none). Pooled SEM were 0.23 and 0.08 for swelling and sensitivity scores, respectively.

affected by treatment differentially over the first 5 days after injection (interaction, P = 0.055).
Swelling scores for mares receiving altrenogest averaged between 0.83 and 1.33 on day 1, and in
general, decreased thereafter. Scores for the LA-150 and LA-225-2 treatments remained higher
than controls on day 2, and the LA-150 again on day 3; no other comparisons were significant (P
> 0.077). Sensitivity scores were not affected (P = 0.3) by treatment or day, and there was no
interaction in the ANOVA.
Discussion
Treatment with all three altrenogest formulations in the current experiment resulted in
similar delays in time to ovulation, averaging about 17 days overall. The mean for the group
receiving LA 150 was 16.8 d, which is equivalent to the mean reported for mares administered
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LA 150 in the experiment of Storer et al. (2009). Both injection volumes of the newer
formulation (LA 225) resulted in ranges of response among mares similar to that in mares
receiving LA 150. Unlike the results of Storer et al. (2009), the CV of days to ovulation for the
LA 150-treated mares was 21% in the present experiment, twice that of the previous experiment
(11%). Moreover, Storer et al. (2009) reported that doubling the volume (hence total dose) of
LA 150 increased the days to ovulation by approximately 4 d, whereas doubling the amount of
LA 225 in the present experiment did not alter the average days to ovulation, nor did it appear to
have any effect on the range of responses among mares. Thus, for practical application, injection
of 1 mL of LA 225 will provide results equivalent to injection of 1.5 mL of LA 150, and
doubling the dose will not provide any better response.
Long-term altrenogest feeding (via Regumate) has been reported to have no detrimental
effect on mares’ health or breeding potential (Squires, 1993). Up to 88 days of feeding had no
effect on clinical signs of health nor on various measurements of blood chemistry and
biochemical endpoints in mares (Shideler et al., 1983). Further examination of mares fed
altrenogest for 0, 15, 30, or 60 days in the breeding season revealed that subsequent pregnancy
rates were unaffected (Squires et al., 1983). Thus, similar application of altrenogest via LA 225
as described herein should provide a method for long-term suppression of estrus and ovulation in
mares that would not be expected to have any detrimental effect on the mares. Weekly injections
of 1 mL of LA 225 would provide constant suppression, based on the results of this experiment,
and this could likely be extended to every 10 days with the use of 2 mL of LA 225. From an
economic standpoint, the 1 mL dose weekly would probably be chosen.
As depicted in Figure 2.1, all mares treated with altrenogest eventually ovulated, but 7 of
the 18 did not exhibit estrus in association with the ovulation. Mares were not followed beyond 5
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days after ovulation, but it is assumed that they would have returned to estrus after the end of the
subsequent diestrus. Although lack of behavioral estrus has been noted to occur in 26% of mares
treated with prostaglandin-F2α (Munro et al., 1979), the time between prostaglandin-F2α treatment
prior to altrenogest administration and the eventual subsequent ovulation makes it unlikely that
prostaglandin-F2α was having any effect in this case. More likely is the possibility that the
threshold concentration of altrenogest in the blood for suppression of ovulation is slightly greater
than that for suppression of behavioral estrus. This means that use of LA 225 for suppression of
estrus may require fewer injections (or longer spacing in time) than for suppression of ovulation,
especially if a normal diestrus follows the delayed ovulation, which would provide another 14
days of diestrus without any further altrenogest injection.
Injection of all formulations/volumes of altrenogest resulted in temporary but slight
swelling at the site of injection. Depending on the use of the mare being treated (e.g., show mare
vs. a racing mare), this slight swelling may be a factor in choosing a treatment option. The
injections in the present experiment were given in the base of the neck anterior to the shoulder.
Although there was slight swelling, actual sensitivity in the area was rare, as indicated by the
average scores all being < 0.25. Again, depending on the use of the mare, alternate sites could
easily be rotated such that any swelling would have minimal effect on performance.
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CHAPTER III
EVALUATION OF A SUSTAINED RELEASE DESLORELIN ACETATE
FORMULATION FOR INHIBITING ESTRUS AND OVULATION IN MARES
Introduction
High doses of GnRH or one of its analogs have been used to down-regulate the
reproductive activity of women (Swerdloff and Heber, 1983) as well as cattle and other
ruminants (D’Occhio et al., 2000). Apparently, the high concentrations of GnRH activity in the
blood in such cases obliterates the normal hypothalamic GnRH signal to the adenohypothesis,
down-regulates GnRH receptors on the gonadotropes, and results in little to no production of LH
from these cells (Ortmann and Diedrich, 1999). Injection of highly active GnRH analog in
biodegradable microspheres is a commonly used procedure for endometriosis in women
(Schweppe and Hummelshoj, 2005).
Unlike human and ruminant females, mares have been less responsive to high-dose
GnRH down-regulation. (Ginther, 1992; Porter et al., 1997). Given the temporary inhibition of
LH and FSH secretion by deslorelin acetate in previous experiments (Johnson et al., 2000, 2002;
Farquhar et al., 2001), it is possible that a larger dose of deslorelin acetate may cause long-term
shut down. Thus, the aim of the present experiment was to test the efficacy of a newly
formulated deslorelin preparation in a biodegradable, slow-release vehicle formulation for
suppression of ovarian activity and estrous activity in mares.
Materials and Methods
Fourteen light horse mares of moderate to high BCS (5 to 8; Henneke et al., 1993) were
used. The mares were long-term residents of the LSU AgCenter Horse Unit in Baton Rouge,
Louisiana, were maintained on local native grass pastures, and received appropriate routine
dewormings and vaccinations. The experiment was conducted in July and August, 2010.
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Mares were checked daily for estrus with a vigorous stallion. On July 17, all mares
received a single i.m. injection (10 mg) of prostaglandin-F2α to lyse any luteal tissue they might
have. Any mare not returning to estrus within 7 days was given a second prostaglandin-F2α
injection on July 24. When a mare came into heat, her ovaries were examined via transrectal
ultrasound scanning to assess follicular sizes and possible ovulation. When a dominant follicle
of at least 30 mm was achieved, a mare was randomly assigned to either 1) control group, and
received an i.m. injection (4 mL) of vehicle (n = 6), or 2) deslorelin-treated group, and received
an i.m. injection of 1.5 g deslorelin acetate in a biodegradable, slow-release vehicle formulation
(4 mL; n = 7). One mare never showed estrus after the two prostaglandin-F2α injections and was
removed from the experiment.
After injections, mares were checked for estrus daily and their ovaries were scanned for
assessment of follicular sizes every 3 days until a follicle of 30 mm or larger was detected.
Mares achieving 30-mm follicles were then scanned daily until ovulation. The disappearance of
a preovulatory follicle (>35 mm) and the presence of a bright echogenic structure at the location
of the previously observed follicle were taken to indicate ovulation. The day of ovulation was
considered the day that the preovulatory follicle was no longer present. In addition, jugular blood
samples were drawn daily, once a mare achieved a 30-mm follicle, until day 5 post-ovulation to
confirm the patterns in progesterone and LH concentrations. These data were used to estimate
date of ovulation based on 1) the first progesterone increase (0.5 ng/mL or higher) occurs
approximately 24 h after ovulation, and 2) the peak in LH concentrations occurs approximately
24 h after ovulation (Ginther, 1992). This approach was found to be a reliable backup to
ultrasound scanning in a previous experiment (Storer et al., 2009).
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Estrous behavior was scored based on behavioral signs at each assessment. Mares
nonreceptive to the stallion (diestrus) received scores of -3, -2, or -1, based on the degree of
negativity they displayed; behavioral signs including kicking, biting, holding ears back,
switching of tail, or holding tail down tightly. Passive mares (mares failing to show either
positive or negative signs) were scored as 0. Mares displaying signs typical of estrus (lordosis
reflex, urinating, raising of the tail, or clitoral eversion) were scored as 1, 2, or 3, based on the
intensities of the signs.
Days to ovulation were analyzed in a one-way ANOVA (SAS) with treatment as the
single factor. Percentage of mares expressing heat at the expected time for return to estrus was
analyzed by coding (0 = no expression, 1 = expression of estrus); these data were also analyzed
by one-way ANOVA.
Results
Mean numbers of days until estrus, for those mares exhibiting a post-treatment estrus, are
presented in Figure 3.1. Neither the days to first estrus nor the days to ovulation differed
between groups (P > 0.1). The proportion of mares exhibiting estrus at the expected time did
differ (P = 0.77) between groups; all 6 of the control mares (100%) exhibited estrus but only 4 of
the 7 deslorelin-treated mares did (57%).
Discussion
The dose of deslorelin acetate used in the present experiment (1.5 g) was approximately
700 times greater than that used in Ovuplant (2.1 mg deslorelin as deslorelin acetate). Although
the inhibition of LH and FSH secretion caused by Ovuplant use in mares was generally
temporary (Johnson et al., 2000, 2002; Farquhar et al., 2001), lasting approximately 10 days or
less (Johnson et al., 2002), a small percentage of mares seemed to be hypersensitive to
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Figure 3.1. Mean days to first estrus (left panel) and ovulation (right panel) in control mares (n =
6) and mares treated with 1.5 g of deslorelin acetate in a biodegradable, slow-release formulation
(n = 7). All 6 of the control mares, but only 4 of the treated mares, displayed estrus at the
expected time of return to estrus. All mares ovulated around the expected time. There was no
difference (P > 0.1) between groups for either endpoint. Pooled SEM were 1.0 and 0.9 days for
days to first estrus and days to ovulation, respectively.

deslorelin, in the form of Ovuplant, and would go into an anestrous state and be lost for the
breeding season (Johnson et al., 2000). McCue et al. (2002) subsequently reported that removal
of the implant (Ovuplant) within 48 h of insertion resulted in normal interovulatory intervals in
mares. Thus, the detrimental effect of Ovuplant seemed to be in the timing of the exposure to the
peptide. More recent data (Stich et al., 2004) has confirmed that liquid formulations of deslorelin
do not result in follicular suppression and extended interovulatory periods. The slow-release
formulation used in the present experiment should have resulted in elevated plasma
concentrations of deslorelin for a much longer time than those produced by Ovuplant. However,
there was no effect of treatment in the present experiment on time to ovulation and little effect on
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time to first estrus. Thus, it is apparent that this approach (i.e., dose of deslorelin and vehicle
formulation) to inhibiting estrus and ovulation in mares has basically no promise as a practical
application.
Why this approach had no effect on time to ovulation, when a much smaller dose of
deslorelin in the form of Ovuplant consistently did in several experiments (Johnson et al., 2000,
2002; Farquhar et al., 2001), raises the question as to what actually was the basis of the Ovuplant
inhibition. Given that the Ovuplant effect (lengthening) on interovulatory interval was avoided if
the capsule was removed within 48 h after implantation (McCue et al, 2002), it must be assumed
that the inhibitory effect on LH and FSH secretion reported by Johnson et al.(2000, 2002) was
occurring in the first 48 h after implantation. This assumption really needs to be tested in an
empirical experiment: treat a group mares with Ovuplant, and remove the implant from half the
mares after 48 h. Measurement of daily LH and FSH concentrations, in a manner similar to that
of Johnson et al. (2000), in those mares plus a control group would provide direct evidence of
whether all the inhibitory effect was in the first 48 h.
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SUMMARY AND CONCLUSIONS
Two experiments were performed to test the efficacies of altrenogest, an artificial
progestogen, and deslorelin acetate, a potent analog of GnRH, in inhibiting estrus and ovulation
in mares displaying normal estrous cycles. Treatment with two doses of a newly formulated
solution of altrenogest in slow-release vehicle was compared to the currently commercially
available formulation (LA 150, 1.5 mL injection) and vehicle injection in mares after induction
of luteolysis. All groups receiving altrenogest had extended periods of diestrus relative to control
mares as well as a delay to next ovulation; there was no difference among the groups receiving
altrenogest for either endpoint. A similar experiment comparing treatment with deslorelin acetate
(1.5 g) in a slow-release formulation to vehicle injection (controls) resulted in no change in days
to first estrus or days to ovulation. Deslorelin treatment did reduce the percentage of mares
displaying estrus at the expected time by about 40%. It is concluded that altrenogest, both in the
established and in the newer formulations, can be used to delay the onset of estrus and ovulation
in normally cycling mares. An injection schedule of approximately once every 10 days could be
used to keep mares out of heat for extended periods of time.
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